Abstract
Background: Despite the significant developments made in the field of diagnosis and treatment modalities of cancer during the last two decades, it still remains one of the most life threatening diseases killing 8.2 million people annually across the globe. It has been well-established that development of chemoresistance in cancer cells is the major cause of failure of chemotherapeutic agents in clinic. Most of the chemotherapeutic agents currently being used activate NF-κB and NF-κB regulated gene products in cancer cells and induce drug resistance. Increasing lines of evidences suggest that NF-κB blockers have high potential in decreasing drug resistance and sensitize cancer cells to chemotherapeutic agents.
Methods: A through literature search was carried out in pubmed to identify natural NF-κB inhibitors that possess high potential in sensitizing cancer cells.
Results: Our literature search retrived a number of NF-κB inhibitors that have been identified during the last several years. Notably, the inhibitors obtained from Mother Nature such as curcumin, tocotrienol, resveratrol, garcinol etc. are found to be highly safe, efficacious and inexpensive. Many preclinical and clinical studies have revealed that these agents can block the activation of NF-κB in cancer cells to overcome drug resistance and make them sensitive to chemotherapeutic agents.
Conclusion: Both basic and clinical research revealed that constitutive activation of NF-κB is the prime reason for inducing drug resistance in cancer cells. This comprehensive review scientifically evaluates the chemosensitizing potential of these natural agents which serve as potent NF-κB blockers, based on evidence based literature.
Keywords: Cancer, chemoresistance, NF-κB, chemosensitization, natural products.
Current Pharmaceutical Design
Title:NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization
Volume: 22 Issue: 27
Author(s): Javadi Monisha, Ganesan Padmavathi, Nand Kishor Roy, Anindita Deka, Devivasha Bordoloi, Anand Anip and Ajaikumar B. Kunnumakkara
Affiliation:
Keywords: Cancer, chemoresistance, NF-κB, chemosensitization, natural products.
Abstract: Background: Despite the significant developments made in the field of diagnosis and treatment modalities of cancer during the last two decades, it still remains one of the most life threatening diseases killing 8.2 million people annually across the globe. It has been well-established that development of chemoresistance in cancer cells is the major cause of failure of chemotherapeutic agents in clinic. Most of the chemotherapeutic agents currently being used activate NF-κB and NF-κB regulated gene products in cancer cells and induce drug resistance. Increasing lines of evidences suggest that NF-κB blockers have high potential in decreasing drug resistance and sensitize cancer cells to chemotherapeutic agents.
Methods: A through literature search was carried out in pubmed to identify natural NF-κB inhibitors that possess high potential in sensitizing cancer cells.
Results: Our literature search retrived a number of NF-κB inhibitors that have been identified during the last several years. Notably, the inhibitors obtained from Mother Nature such as curcumin, tocotrienol, resveratrol, garcinol etc. are found to be highly safe, efficacious and inexpensive. Many preclinical and clinical studies have revealed that these agents can block the activation of NF-κB in cancer cells to overcome drug resistance and make them sensitive to chemotherapeutic agents.
Conclusion: Both basic and clinical research revealed that constitutive activation of NF-κB is the prime reason for inducing drug resistance in cancer cells. This comprehensive review scientifically evaluates the chemosensitizing potential of these natural agents which serve as potent NF-κB blockers, based on evidence based literature.
Export Options
About this article
Cite this article as:
Monisha Javadi, Padmavathi Ganesan, Roy Kishor Nand, Deka Anindita, Bordoloi Devivasha, Anip Anand and Kunnumakkara B. Ajaikumar, NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization, Current Pharmaceutical Design 2016; 22 (27) . https://dx.doi.org/10.2174/1381612822666160609110231
DOI https://dx.doi.org/10.2174/1381612822666160609110231 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Androgen Receptor in Human Health: A Potential Therapeutic Target
Current Drug Targets Biomarker Diversity, Validation and Clinical Translation: Tenets for Emergent Personalized Medicine Initiatives
Current Pharmacogenomics and Personalized Medicine Radiolabelled Oligonucleotides for Imaging of Gene Expression with PET
Current Medicinal Chemistry An Overview of Acute Flaccid Myelitis
CNS & Neurological Disorders - Drug Targets Improving Cancer Therapeutics by Molecular Profiling
Current Drug Metabolism Pharmacotherapy for the Metabolic Syndrome
Current Vascular Pharmacology Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment
Current Medicinal Chemistry Clinical Use of Therapies Targeting Tumor Vasculature and Stroma
Current Cancer Drug Targets CD47 Functionalization of Nanoparticles as a Poly(ethylene glycol) Alternative: A Novel Approach to Improve Drug Delivery
Current Drug Targets Ligands and Therapeutic Perspectives of Adenosine A2A Receptors
Current Pharmaceutical Design Mammaglobin-Based Strategies for Treatment of Breast Cancer
Current Cancer Drug Targets Modular Nanotransporters for Targeted Intracellular Delivery of Drugs: Folate Receptors as Potential Targets
Current Pharmaceutical Design Deubiquitinating Enzymes as Therapeutic Targets in Cancer
Current Pharmaceutical Design Nanocarriers for Gene Delivery - Polymer Structure, Targeting Ligands and Controlled-Release Devices
Current Nanoscience Cyclooxygenase-2 Inhibitors: A Painful Lesson
Cardiovascular & Hematological Disorders-Drug Targets Management of the Menopausal Disturbances and Oxidative Stress
Current Pharmaceutical Design Targeted Delivery of Montelukast for the Treatment of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Targeting Nodal and Cripto-1: Perspectives Inside Dual Potential Theranostic Cancer Biomarkers
Current Medicinal Chemistry The Pathogenic Role of Intestinal Flora in IBD and Colon Cancer
Current Drug Targets Garlic and its Active Compounds: A Potential Candidate in The Prevention of Cancer by Modulating Various Cell Signalling Pathways
Anti-Cancer Agents in Medicinal Chemistry